- ISIN
- US1420381089
- CUSIP
- 142038108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 23, 2021
Highlights
- Market Cap
- $157.21M
- Enterprise Value
- $173.39M
- EPS (TTM)
- -$1.41
- Total Revenue (TTM)
- $8.81M
- Gross Profit (TTM)
- $7.49M
- EBITDA (TTM)
- -$115.23M
- Year Range
- $1.22 - $3.54
- Target Price
- $5.00
- ROA (TTM)
- -89.41%
- ROE (TTM)
- -130.58%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CRBU Performance Chart
Caribou Biosciences, Inc. (CRBU) is up 3.1% since the beginning of the year. At $2 per share, CRBU is trading 53.6% below its 52-week high of $4.
Loading charts...
Returns By Period
Caribou Biosciences, Inc. (CRBU) has returned 3.14% so far this year and 22.39% over the past 12 months.
Caribou Biosciences, Inc.
- 1D
- 0.00%
- 1M
- -21.90%
- YTD
- 3.14%
- 6M
- -4.65%
- 1Y
- 22.39%
- 3Y*
- -27.65%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CRBU Monthly Returns History
Based on dividend-adjusted daily data since Jul 23, 2021, CRBU's average daily return is -0.04%, while the average monthly return is -0.80%.
Historically, 35% of months were positive and 65% were negative. The best month was Jul 2023 with a return of +69.2%, while the worst month was Jun 2024 at -43.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.
On a daily basis, CRBU closed higher 45% of trading days. The best single day was Jul 6, 2023 with a return of +45.6%, while the worst single day was Mar 12, 2024 at -30.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.32% | 34.75% | -0.00% | -1.05% | 25.53% | -30.51% | 3.14% | ||||||
| 2025 | -10.06% | -18.18% | -21.96% | -6.81% | 24.57% | 18.87% | 61.11% | -7.88% | 24.60% | 3.86% | -19.83% | -18.04% | 0.00% |
| 2024 | 6.98% | 29.04% | -35.02% | -29.38% | -20.66% | -43.06% | 41.46% | -6.90% | -9.26% | 0.00% | 11.73% | -27.40% | -72.25% |
| 2023 | 14.81% | -15.53% | -12.81% | -19.02% | 2.56% | -3.63% | 69.18% | -18.08% | -18.85% | -24.06% | 61.71% | -2.39% | -8.76% |
| 2022 | -28.89% | -6.99% | -8.02% | -19.39% | 12.57% | -34.81% | 49.54% | 21.55% | 6.89% | -7.68% | -4.41% | -32.55% | -58.38% |
| 2021 | -8.22% | 67.90% | -12.24% | -7.37% | -15.92% | -18.83% | -14.50% |
Benchmark Metrics
Caribou Biosciences, Inc. has an annualized alpha of -29.18%, beta of 1.86, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since July 23, 2021.
- This stock participated in 234.95% of S&P 500 Index downside but only 100.67% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -29.18%
- Beta
- 1.86
- R²
- 0.13
- Upside Capture
- 100.67%
- Downside Capture
- 234.95%
Return for Risk
Risk / Return Rank
CRBU ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Caribou Biosciences, Inc. (CRBU) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRBU | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.75 | ||
| Sortino ratioReturn per unit of downside risk | -1.74 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.37 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 0.44 | 2.78 | -2.34 |
| Martin ratioReturn relative to average drawdown | 0.75 | 12.44 | -11.69 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Caribou Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Caribou Biosciences, Inc. was 97.58%, occurring on Apr 16, 2025. The portfolio has not yet recovered.
The current Caribou Biosciences, Inc. drawdown is 94.59%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.58%Apr 2025 | 3y 7mo | — | 4y 9moSep 2021 - now |
2021 correction2021 | -15.94%Aug 2021 | 6d | 4d | 10dAug 2021 - Sep 2021 |
2021 correction2021 | -15.80%Aug 2021 | 1d | 11d | 12dAug 2021 - Aug 2021 |
2021 correction2021 | -10.76%Jul 2021 | 5d | 7d | 12dJul 2021 - Aug 2021 |
Drawdown Indicators
| CRBU | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.58% | -56.78% | -40.80% |
Max Drawdown (1Y)Largest decline over 1 year | -51.06% | -9.10% | -41.96% |
Max Drawdown (3Y)Largest decline over 3 years | -91.12% | -18.90% | -72.22% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -94.59% | -1.80% | -92.79% |
Average DrawdownAverage peak-to-trough decline | -79.38% | -10.71% | -68.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.02% | 2.03% | +27.99% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Caribou Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Caribou Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CRBU relative to other companies in the Biotechnology industry. Currently, CRBU has a P/S ratio of 17.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CRBU in comparison with other companies in the Biotechnology industry. Currently, CRBU has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CRBU
Add Caribou Biosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CRBU